Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Emanuela Dell’Aquila, Grazia Armento, Michele Iuliani, Sonia Simonetti, Loretta D’Onofrio, Tea Zeppola, Cristina Madaudo, Marco Russano, Fabrizio Citarella, Giulia Ribelli, Francesco Pantano, Bruno Vincenzi, Giuseppe Tonini & Daniele Santini. (2020) Denosumab for cancer-related bone loss. Expert Opinion on Biological Therapy 20:11, pages 1261-1274.
Read now
Read now
A. Ludwig Meiss, Florian Barvencik, Kornelia Babin & Gerald Eggers-Stroeder. (2017) Denosumab and surgery for the treatment of Perthes’ disease in a 9-year-old boy: favorable course documented by comprehensive imaging— a case report. Acta Orthopaedica 88:3, pages 354-357.
Read now
Read now
Zeina A. Habib. (2017) Bisphosphonates in the treatment of osteoporosis: a review of skeletal safety concerns. Expert Review of Endocrinology & Metabolism 12:1, pages 59-71.
Read now
Read now
Sunil J. Wimalawansa. (2016) Optimum duration and safety of long-term use of potent anti-resorptive medications in osteoporosis. Expert Review of Endocrinology & Metabolism 11:4, pages 329-348.
Read now
Read now
Maurizio Rossini, Giovanni Adami, Silvano Adami, Ombretta Viapiana & Davide Gatti. (2016) Safety issues and adverse reactions with osteoporosis management. Expert Opinion on Drug Safety 15:3, pages 321-332.
Read now
Read now
Articles from other publishers (32)
Courtney Ng, Yongli Qin, Yuhan Xia, Xiaoyu Hu & Baohong Zhao. (2023) Jagged1 Acts as an RBP-J Target and Feedback Suppresses TNF-Mediated Inflammatory Osteoclastogenesis. The Journal of Immunology.
Crossref
Crossref
Yannick Rau, Jasper Amtsfeld, Nils Reimers, Ludwig Matrisch, Jasper Frese & Arndt-Peter Schulz. (2023) The development, incidence and treatment trends of trochanteric fractures in Germany: a cohort study. Journal of Orthopaedic Surgery and Research 18:1.
Crossref
Crossref
David A. Hart. (2023) Are secondary effects of bisphosphonates on the vascular system of bone contributing to increased risk for atypical femoral fractures in osteoporosis?. BioEssays 45:4.
Crossref
Crossref
Yuhan Xia, Kazuki Inoue, Yong Du, Stacey J. Baker, E. Premkumar Reddy, Matthew B. Greenblatt & Baohong Zhao. (2022) TGFβ reprograms TNF stimulation of macrophages towards a non-canonical pathway driving inflammatory osteoclastogenesis. Nature Communications 13:1.
Crossref
Crossref
Gengyang Shen, Xin Liu, Wei Lei, Rong Duan & Zhenqiang Yao. (2022) Plumbagin is a NF-κB-inducing kinase inhibitor with dual anabolic and antiresorptive effects that prevents menopausal-related osteoporosis in mice. Journal of Biological Chemistry 298:4, pages 101767.
Crossref
Crossref
Zhenqiang Yao, Stephen J. Getting & Ian C. Locke. (2021) Regulation of TNF-Induced Osteoclast Differentiation. Cells 11:1, pages 132.
Crossref
Crossref
Aquila Gopaul, Tharsan Kanagalingam, Jenny Thain, Tayyab Khan, Andrea Cowan, Nabil Sultan & Kristin K. Clemens. (2021) Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety. Archives of Osteoporosis 16:1.
Crossref
Crossref
Yoshiya Tanaka, Tsutomu Takeuchi, Satoshi Soen, Hisashi Yamanaka, Toshiyuki Yoneda, Sakae Tanaka, Takaya Nitta, Naoki Okubo, Harry K. Genant & Désirée van der Heijde. (2021) Effects of Denosumab in Japanese Patients With Rheumatoid Arthritis Treated With Conventional Antirheumatic Drugs: 36-month Extension of a Phase III Study. The Journal of Rheumatology 48:11, pages 1663-1671.
Crossref
Crossref
Ebrahim Bani Hassan, Nancy Doyle, Jean-Guy Bienvenu, Andrew Stent, Gilles J. Guillemin & Gustavo Duque. (2021) Evaluating the toxicity of escalating dose of oral picolinic acid in Sprague-Dawley rats. Toxicology 462, pages 152960.
Crossref
Crossref
Lanny V. Griffin, Elizabeth Warner, Saroj Palnitkar, Shijing Qiu, Mahalakshmi Honasoge, Shawna G. Griffin, George Divine & Sudhaker D. Rao. (2021) Bone Nanomechanical Properties and Relationship to Bone Turnover and Architecture in Patients With Atypical Femur Fractures: A Prospective Nested Case‐Control Study. JBMR Plus 5:9.
Crossref
Crossref
Sayed Hashim AlQarooniUgo RuggieroSri Priya Suresh. (2021) Atypical fractures secondary to bisphosphonate therapy: A case series and pictorial review. Indian Journal of Musculoskeletal Radiology 3, pages 45-53.
Crossref
Crossref
Javier Martínez-Reina, José L. Calvo-Gallego & Peter Pivonka. (2021) Combined Effects of Exercise and Denosumab Treatment on Local Failure in Post-menopausal Osteoporosis–Insights from Bone Remodelling Simulations Accounting for Mineralisation and Damage. Frontiers in Bioengineering and Biotechnology 9.
Crossref
Crossref
David Louis Perrin, Julia D. Visgauss, David A. Wilson, Anthony M. Griffin, Albiruni R. Abdul Razak, Peter C. Ferguson & Jay S. Wunder. (2021) The role of Denosumab in joint preservation for patients with giant cell tumour of bone. The Bone & Joint Journal 103-B:1, pages 184-191.
Crossref
Crossref
Gonzalo MariscalJorge H. NuñezSanjay BhatiaCarlos BarriosPedro Domenech-Fernández. (2020) Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 39:2, pages 29-36.
Crossref
Crossref
N.H. Rasmussen, J. Dal, F. de Vries, J.P. van den Bergh, M.H. Jensen & P. Vestergaard. (2019) Diabetes and fractures: new evidence of atypical femoral fractures?. Osteoporosis International 31:3, pages 447-455.
Crossref
Crossref
J. Brett Goodloe, Sarah Toner, Alyssa Althoff, Leah Herzog, Stacey Rothwell & Kristoff Reid. (2020) Bilateral Atypical Femur Fractures Complicated by Carbon Fiber Cephalomedullary Nail Fracture. JBJS Case Connector 10:3, pages e20.00182-e20.00182.
Crossref
Crossref
E. Michael Lewiecki. 2020. Osteoporosis. Osteoporosis
309
322
.
E. Michael Lewiecki. (2018) New and emerging concepts in the use of denosumab for the treatment of osteoporosis. Therapeutic Advances in Musculoskeletal Disease 10:11, pages 209-223.
Crossref
Crossref
Tsutomu SugiharaMitsuru KoizumiKeiko HayakawaYoshinori ItoNaohiro Sata. (2018) Impending Atypical Femoral Fracture in a Patient of Breast Cancer With Bone Metastases Receiving Long-term Denosumab. Clinical Nuclear Medicine 43:5, pages 365-366.
Crossref
Crossref
Joseph L. Shaker. (2017) Stress and Insufficiency Fractures. Clinical Reviews in Bone and Mineral Metabolism 16:1, pages 3-15.
Crossref
Crossref
Kenneth Pittman, Yoland C Antill, Amanda Goldrick, Jeffrey Goh & Richard H de Boer. (2017) Denosumab: Prevention and management of hypocalcemia, osteonecrosis of the jaw and atypical fractures. Asia-Pacific Journal of Clinical Oncology 13:4, pages 266-276.
Crossref
Crossref
Ammar Ismail, Amira Hassan Bekhet, Abdelrahman Ibrahim Abushouk, Sahar Mirbaha & Alireza Baratloo. (2017) Denosumab and Atypical Femoral Fractures: A Scoping Literature Review. Trauma Monthly 23:1.
Crossref
Crossref
Moin Khan, Angela M. Cheung & Aliya A. Khan. (2017) Drug-Related Adverse Events of Osteoporosis Therapy. Endocrinology and Metabolism Clinics of North America 46:1, pages 181-192.
Crossref
Crossref
Christina V. OlesonMendel Kupfer & Christina V. Oleson. 2017. Osteoporosis Rehabilitation. Osteoporosis Rehabilitation
193
223
.
Michael F. Holick. 2017. Essentials of Menopause Management. Essentials of Menopause Management
145
164
.
Giuseppe Toro, Cristina Ojeda-Thies, Giampiero Calabrò, Gabriella Toro, Antimo Moretti, Guillermo Martínez-Díaz Guerra, Pedro Caba-Doussoux & Giovanni Iolascon. (2016) Management of atypical femoral fracture: a scoping review and comprehensive algorithm. BMC Musculoskeletal Disorders 17:1.
Crossref
Crossref
F. Vescini, R. Attanasio, A. Balestrieri, F. Bandeira, S. Bonadonna, V. Camozzi, S. Cassibba, R. Cesareo, I. Chiodini, C. Maria Francucci, L. Gianotti, F. Grimaldi, R. Guglielmi, B. Madeo, C. Marcocci, A. Palermo, A. Scillitani, E. Vignali, V. Rochira & M. Zini. (2016) Italian association of clinical endocrinologists (AME) position statement: drug therapy of osteoporosis. Journal of Endocrinological Investigation 39:7, pages 807-834.
Crossref
Crossref
J. Selga, J. H. Nuñez, J. Minguell, M. Lalanza & M. Garrido. (2015) Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review. Osteoporosis International 27:2, pages 827-832.
Crossref
Crossref
Daisuke KajiwaraHiroto KamodaTsukasa YonemotoShintaro IwataTakeshi IshiiToshinori TsukanishiSeiji OhtoriMasashi YamazakiAkihiko Okawa. (2016) Denosumab for Treatment of a Recurrent Cervical Giant-Cell Tumor. Asian Spine Journal 10:3, pages 553.
Crossref
Crossref
Muneaki Ishijima, Yoshitomo Saita, Haruka Kaneko, Mayuko Kinoshita & Kazuo Kaneko. 2016. Osteoporosis in Orthopedics. Osteoporosis in Orthopedics
103
134
.
D. T. Cawley, H. L. Barrett & P. Harrington. (2015) Obliteration of the medullary canal in an atypical bisphosphonate-related femoral fracture. Case Reports 2015:jan07 1, pages bcr2014205439-bcr2014205439.
Crossref
Crossref
Per Aspenberg & Jörg Schilcher. (2014) Atypical Femoral Fractures, Bisphosphonates, and Mechanical Stress. Current Osteoporosis Reports 12:2, pages 189-193.
Crossref
Crossref